Every material Form 8-K Vericel filed with the SEC in 2025, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Vericel reported third quarter 2025 results, with total revenue of $67.5 million, up from $57.9 million a year earlier, and net income of $5.1 million, compared with a net loss of $0.9 million in the prior-year quarter. The company reaffirmed its full-year 2025 MACI revenue and profitability targets and gave total full-year revenue guidance of $272 million to $276 million.
Q3 2025 total revenue was $67.5 million, versus $57.9 million in Q3 2024; MACI revenue grew 25% to $55.7 million.
Net income was $5.1 million, or $0.10 per diluted share, versus a net loss of $0.9 million, or $0.02 per share, a year earlier.
Full-year 2025 total revenue guidance is $272 million to $276 million; full-year gross margin of 74% and adjusted EBITDA margin of 26% were reaffirmed.
As of September 30, 2025, the company had $185 million in cash and investments and no debt.
Vericel reported second quarter 2025 results for the period ended June 30, 2025, with total revenue up 20% to $63.2 million and a net loss of $0.6 million, or $0.01 per diluted share, versus $4.7 million a year earlier. The company reaffirmed its full-year MACI revenue growth and profitability guidance, which matters to shareholders because it shows revenue and earnings improving while the outlook was held steady.
Total net revenue rose to $63.2 million from $52.7 million; MACI net revenue grew 21% to $53.5 million.
Gross margin was 74%, up from 70% a year earlier; non-GAAP adjusted EBITDA rose 112% to $13.4 million.
Full-year 2025 guidance was reaffirmed for MACI revenue growth in the low 20% range and for a 74% gross margin and 26% adjusted EBITDA margin.
As of June 30, 2025, the company had approximately $164 million in cash and investments and no debt.
Vericel reported first-quarter 2025 total revenue of $52.6 million, up from $51.3 million a year earlier, but its net loss widened to $11.2 million, or $0.23 per diluted share, from $3.9 million, or $0.08 per share. The company raised its full-year profitability guidance to a 74% gross margin and 26% adjusted EBITDA margin while reaffirming full-year revenue growth of 20% to 23%.
Q1 2025 total revenue of $52.6 million versus $51.3 million in Q1 2024; MACI net revenue of $46.3 million
Net loss of $11.2 million, or $0.23 per diluted share, versus a net loss of $3.9 million, or $0.08 per share, a year earlier
Full-year profitability guidance raised to 74% gross margin and 26% adjusted EBITDA margin
Second-quarter total revenue growth expected to be 22% to 25%; full-year revenue growth guidance of 20% to 23% reaffirmed
At its April 30, 2025 annual meeting, Vericel shareholders approved an amended and restated 2022 Omnibus Incentive Plan and an amended and restated 2015 Employee Stock Purchase Plan. The plans reserve 5,088,095 and 2,000,000 shares of common stock for issuance, respectively. All seven director nominees were elected, and shareholders also approved the non-binding advisory vote on executive compensation.
Equity plan reserves 5,088,095 shares of common stock for issuance; effective April 30, 2025.
Employee Stock Purchase Plan reserves 2,000,000 shares of common stock.
All seven director nominees elected to one-year terms expiring at the 2026 annual meeting.
Non-binding say-on-pay vote: 40,777,685 votes for and 4,353,149 against.
Vericel reported full-year 2024 total net revenue up 20% to $237.2 million and net income of $10.4 million, or $0.20 per diluted share, compared with a net loss of $3.2 million in 2023. The company reaffirmed 2025 total net revenue growth guidance of 20% to 23% and increased its mid-term profitability targets for 2029, which matters to shareholders because it shows continued growth and a shift to profitability.
Full-year 2024 total net revenue rose 20% to $237.2 million, including $197.3 million of MACI net revenue.
Full-year 2024 net income was $10.4 million, or $0.20 per diluted share, versus a net loss of $3.2 million in 2023.
2025 guidance reaffirmed: total net revenue growth of 20% to 23%, gross margin of 73% to 74%, and adjusted EBITDA margin of 25% to 26%.
Mid-term targets increased: gross margin in the high-70% range and adjusted EBITDA margin in the high-30% range by 2029.
Vericel released preliminary, unaudited results for 2024, projecting total net revenue of about $237 million to $237.5 million, up 20%, and GAAP net income for the full year. It also issued 2025 guidance calling for 20% to 23% revenue growth and raised its mid-term gross margin and adjusted EBITDA margin targets. Shareholders should note that the company says the final audited figures may differ materially from these estimates.
Full-year 2024 total net revenue expected at about $237 million to $237.5 million, up 20%; full-year GAAP net income positive
Fourth-quarter 2024 revenue expected at $75.2 million to $75.7 million; GAAP net income expected at $17.5 million to $18.5 million
2025 guidance: 20% to 23% revenue growth, gross margin of 73% to 74%, adjusted EBITDA margin of 25% to 26%
About $167 million in cash, restricted cash and investments and no debt as of December 31, 2024; figures are preliminary and unaudited
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Vericel filing is on SEC EDGAR ↗. 8-K briefs of other companies →